REPLICor Receives Notice of Allowance for Key Patent Application

Laval, Quebec – Nov. 30^th, 2007 – REPLICor Inc today announced it has received a Notice of Allowance from the U.S. Patent Office for a patent application that covers a large portion of its REP 9C / REP 9AC technology. The patent covers the use of REPLICor’s lead compounds for the treatment of viral diseases including hepatitis C, hepatitis B and influenza. "With this patent allowance, REPLICor is positioned to move aggressively forward with its patented technology targeting most enveloped viruses." said Jean-Marc Juteau, Ph.D., Senior Vice President and responsible for the intellectual property portfolio.